Cooperative Agreement UH3CA283619
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Cancer Institute awarded a $176,040 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) from July 1, 2025 to June 30, 2027 under the Cancer Research Manpower (CFDA 93.398) federal grant program. The goal of this project is to develop new strategies to engineer CAR-T cells that can overcome the cancer cell glycocalyx barrier in solid tumors. This will involve: (1) engineering CAR-T cells to strengthen the immune synapse by enhancing binding to the...
- This $118,722 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to develop a novel immunotherapy for pancreatic cancer. The grant funding will be used by Emory University to engineer CD4+ T cells expressing high levels of the enzyme CD26 and equip them with a chimeric antigen receptor (CAR) targeting mesothelin, a protein expressed on pancreatic tumor cells. The research aims to harness the favorable properties of CD26+ T cells to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $635,248 to Trustees of Boston University to develop a novel self-amplifying ribonucleic acid (SARNA) technology encoding a bispecific T cell engager (BITE) antibody for the treatment of lung cancer. The key goals are to: Design 5-methylcytidine (5MC) modified SARNA constructs encoding BITE antibodies and evaluate their protein expression performance in vitro. Assess the in vitro and in...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $620,820.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of the transcription factor CREB5 in driving immune therapy resistance in cancer. The research aims to: 1) understand the molecular mechanisms governing CREB5 regulation and transcription, 2) identify CREB5-interacting proteins that drive collagen matrix...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,181,683 to the Dana-Farber Cancer Institute in Boston, MA to conduct research aimed at enhancing immune checkpoint blockade responsiveness and tertiary lymphoid structure formation through CD4+TFHx13 CAR-T cells to achieve cures for clear cell renal cell carcinoma (CCRCC). The research will involve experimental design and computational analysis of...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at deconvoluting the heterogeneity of chimeric antigen receptor (CAR) T cells in order to engineer durable antitumor immunity. The research project, which runs from January 1, 2025 to December 31, 2029, will use dynamic lineage recording to understand how individual CAR T cell subsets behave in vivo and...
- The federal Cooperative Agreement award for "Next Generation T Cell Therapies for Mutant KRAS Solid Tumors" was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,238,704 award supports the early-stage clinical testing of a novel T cell receptor (TCR1020) therapy targeting the KRAS G12V mutation in solid tumors. The project aims to develop genetically modified T cells to overcome resistance mechanisms and promote durable tumor regression. Key...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
- This $414,803 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the Massachusetts Institute of Technology (MIT) to develop improved T cell receptor (TCR) engineering strategies for TCR-T cell cancer immunotherapy. The key products and services to be delivered under this grant include: Implementing high-throughput library screens of TCR constant region variants to identify mutations that can improve TCR signaling strength, with...
- This Project Grant, awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), funds the development and validation of a novel armored CAR-T immunotherapeutic for the treatment of pancreatic ductal adenocarcinoma (PDAC). The $400,835 award to Cambium Oncology LLC aims to engineer CAR-T cells that can secrete a VIP receptor antagonist to disrupt the immunosuppressive tumor microenvironment in PDAC. The 1-year project involves developing and validating...